Biophytis S.A. (BPTSY) - Total Liabilities
Based on the latest financial reports, Biophytis S.A. (BPTSY) has total liabilities worth $15.13 Million USD as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BPTSY long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Biophytis S.A. - Total Liabilities Trend (2012–2023)
This chart illustrates how Biophytis S.A.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Biophytis S.A. balance sheet assets.
Biophytis S.A. Competitors by Total Liabilities
The table below lists competitors of Biophytis S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gencell Ltd
TA:GNCL
|
Israel | ILA2.90 Million |
|
Zelira Therapeutics Ltd
AU:ZLD
|
Australia | AU$5.59 Million |
|
Henderson High Income Trust
LSE:HHI
|
UK | GBX67.03 Million |
|
DTCOM - Direct to Company S.A
SA:DTCY3
|
Brazil | R$6.07 Million |
|
Capitan Investment Ltd
V:CAI
|
Canada | CA$1.24 Million |
|
Henderson International Income Trust PLC
LSE:HINT
|
UK | GBX40.28 Million |
|
Anagenics Ltd
AU:AN1
|
Australia | AU$1.82 Million |
|
Inhalerx Ltd
AU:IRX
|
Australia | AU$2.38 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Biophytis S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Biophytis S.A.'s balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biophytis S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biophytis S.A. (2012–2023)
The table below shows the annual total liabilities of Biophytis S.A. from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $15.85 Million | -33.68% |
| 2022-12-31 | $23.90 Million | -21.79% |
| 2021-12-31 | $30.56 Million | +49.95% |
| 2020-12-31 | $20.38 Million | -19.13% |
| 2019-12-31 | $25.20 Million | +69.61% |
| 2018-12-31 | $14.86 Million | +212.04% |
| 2017-12-31 | $4.76 Million | +22.90% |
| 2016-12-31 | $3.87 Million | +109.34% |
| 2015-12-31 | $1.85 Million | +22.09% |
| 2014-12-31 | $1.52 Million | +46.15% |
| 2013-12-31 | $1.04 Million | -4.36% |
| 2012-12-31 | $1.08 Million | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more